Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical is attractive fundamentally because its LIBERTY platform has expanded to 44 issued patents and 49 pending applications, strengthening protection around an FDA-cleared, single-use robotic system as commercial rollout broadens. Adoption is being reinforced by system-level VAC approvals at major accounts such as the University of Pennsylvania, University of North Carolina, Mass General, and Beth Israel, with repeat orders, deeper utilization, and no need for incremental selling effort on reorders. Despite a 2Q26 operating loss of $6.2M and net loss of $5.6M, the company ended 2Q with $67.4M of cash and no debt, while margin improvement is expected as manufacturing efficiencies reduce cost of revenue and support a path toward positive gross margins.

Microbot Medical is viewed negatively because it is transitioning from a development-stage company with no prior revenue history to commercial operations, making execution risk on the LIBERTY launch especially high. Its business depends on successful salesforce deployment, physician training, customer support, and broad market adoption, while slower-than-expected uptake, competition, reimbursement changes, and uncertain expansion into coronary and neurovascular uses could weaken the commercialization path. Financially, monthly cash burn is expected to rise significantly as commercial activities scale, and although it has a 24- to 36-month runway and $68.5M of cash in the valuation framework, dependence on contract manufacturing in Israel adds dilution, supply chain, and geopolitical risk.